Global $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Region


Dublin, Jan. 11, 2024 (GLOBE NEWSWIRE) -- The "Global Women's Health Market Size, Share & Trends Analysis Report by Application (Postmenopausal Osteoporosis, Infertility, Endometriosis & Uterine Fibroids, Menopause, PCOS), Age, Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

The global women's health market size is expected to reach USD 67.07 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030. The introduction of innovative novel products and the presence of a strong pipeline of women's health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

Market Dynamics

  • Market Driver Analysis
    • Rising Incidence of Target Diseases
    • Increasing Initiatives by Government and Various Organizations
    • Rising Publicly Funded Family Planning Services
  • Market Restraint Analysis
    • Patent Expiry of Major Drugs
    • Lawsuits Related to Products
    • Adverse Effects Associated With Use of Contraceptive Drugs and Devices



For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women's health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Women's Health Market Report Highlights

  • The contraceptives segment held the highest market share of more than 35.25% of the global revenue in 2023 due to increased awareness about family planning and rapid technological advancements in contraception
  • The University of California Bixby Center released a reimbursement guide to help health providers offer women a full range of contraceptives
  • The endometriosis segment is expected to witness significant growth over the forecast period due to the launch of products, such as Relugoliz and the impending launch of Linzagolix for the treatment of women with uterine fibroids
  • Based on age, the 50 years and above segment is expected to register the fastest growth rate of 6.7% over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe
  • According to the International Menopause Society, globally, women aged between 45 and 55 years typically experience menopause, with the average age of onset at 51.5 years

Companies Profiled

  • AbbVie, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Agile Therapeutics
  • Amgen, Inc.
  • Apothecus Pharmaceutical Corp.
  • Blairex Laboratories, Inc.
  • Ferring B.V.

Key Attributes

Report AttributeDetails
No. of Pages130
Forecast Period2023-2030
Estimated Market Value (USD) in 2023$44.36 Billion
Forecasted Market Value (USD) by 2030$67.07 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal

Key Topics Covered

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Women's Health Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.3. Women's Health Market Analysis Tools

Chapter 4. Women's Health Market: Application Estimates & Trend Analysis
4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Women's Health Market by Application Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

Chapter 5. Women's Health Market: Age Estimates & Trend Analysis
5.1. Treatment Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Women's Health Market by Age Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

Chapter 6. Women's Health Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
6.5. North America
6.6. Europe
6.7. Asia-Pacific
6.8. Latin America
6.9. MEA

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape

For more information about this report visit https://www.researchandmarkets.com/r/4axn4h

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Global Women’s Health Market

Coordonnées